NCT04922021: A reported trial by LEO Pharma
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT04922021 |
|---|---|
| Title | A Phase 2a, Randomized, Double-blind, Placebo-controlled, Multi-site, Proof of Concept Trial to Evaluate the Efficacy and Safety of LEO 138559 in Adult Subjects With Moderate to Severe Atopic Dermatitis (AD). |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | July 14, 2021 |
| Completion date | June 2, 2022 |
| Required reporting date | June 2, 2023, midnight |
| Actual reporting date | June 2, 2023 |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | None |